Sacubitril/valsartan as a component of therapy for chronic heart failure

Abstract

Chronic heart failure is in the vast majority of cases the outcome of many cardiovascular diseases. Despite significant achievements in the early diagnosis and treatment of cardiological pathology, the prevalence of chronic heart failure is steadily increasing, increasing the material costs of the healthcare system. Experts explain this aspect by the aging of the population of the developed countries of the world due to an increase in life expectancy. The presented review highlights the possibilities of using sacubitril/valsartan in clinical practice in order to inhibit the progression of chronic heart failure.

Keywords

sacubitril/valsartan / chronic heart failure / coronary heart disease / arterial hypertension

References

[1] Rossiiskoe kardiologicheskoe obshchestvo. Khronicheskaya serdechnaya nedostatochnost’. Klinicheskie rekomendatsii 2020. Rossiiskii kardiologicheskii zhurnal. 2020;25(11). DOI: 10.15829/1560-4071-2020-4083

[2] Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 11.DOI: 10.15829/1560-4071-2020-4083

[3] Danilov AI, Careva VM, Shpuntov MG, Drobot NV. Possibilities of Using aldosterone antagonists in patients with chronic heart failure. Trudnyj Pacient. 2019;17(5):6–8. (In Russ.)

[4] Данилов А.И., Царева В.М., Шпунтов М.Г., Дробот Н.В. Возможности применения антагонистов альдостерона у пациентов с хронической сердечной недостаточностью // Трудный пациент. 2019. Т. 17, № 5. С. 6–8.

[5] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. DOI: 10.1093/eurheartj/ehw128

[6] Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur Heart J. 2016. Vol. 37, No. 27. P. 2129–2200. DOI: 10.1093/eurheartj/ehw128

[7] McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242–247. DOI: 10.1002/ejhf.250

[8] McMurray J.J. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances // Eur J Heart Fail. 2015. Vol. 17, No. 3. P. 242–247. DOI: 10.1002/ejhf.250

[9] Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57–77.DOI: 10.1042/CS20150469

[10] Volpe M., Carnovali M., Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment // Clin Sci (Lond). 2016. Vol. 130, No. 2. P. 57–77. DOI: 10.1042/CS20150469

[11] Napalkov DA, Zhilenko AV, Sulimov VA. Renin-angiotensin-aldosterone system and chronic heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2009;2(4):4–7. (In Russ.)

[12] Напалков Д.А., Жиленко А.В., Сулимов В.А. Ренин-ангиотензин-альдостероновая система и хроническая сердечная недостаточность // Кардиология и сердечно-сосудистая хирургия. 2009. Т. 2, № 4. С. 4–7.

[13] Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34(12):886–893. DOI: 10.1093/eurheartj/ehs262

[14] Mangiafico S., Costello-Boerrigter L.C., Andersen I.A., et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics // Eur Heart J. 2013. Vol. 34, No. 12. P. 886–893. DOI: 10.1093/eurheartj/ehs262

[15] Nikiforov VS. Kombinirovannyi preparat sakubitril/valsartan — novyi etap v lechenii khronicheskoi serdechnoi nedostatochnosti. Medical Council. 2020;14:34–39. (In Russ.)

[16] Никифоров В.С. Комбинированный препарат сакубитрил/валсартан — новый этап в лечении хронической сердечной недостаточности // Медицинский совет. 2020. Т. 14. С. 34–39.

[17] Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch Med Sci. 2017;13(5):1207–1216. DOI: 10.5114/aoms.2017.68813

[18] Yandrapalli S., Aronow W.S., Mondal P., Chabbott D.R. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan // Arch Med Sci. 2017.Vol. 13, No. 5. P. 1207–1216. DOI: 10.5114/aoms.2017.68813

[19] Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639–653. DOI: 10.1016/j.jacc.2016.04.060

[20] Bayes-Genis A., Barallat J., Richards A.M. A test in context: neprilysin: function, inhibition, and biomarker // J Am Coll Cardiol. 2016. Vol. 68, No. 6. P. 639–653. DOI: 10.1016/j.jacc.2016.04.060

[21] Jhund PS, McMurray JJV. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102(17):1342–1347. DOI: 10.1136/heartjnl-2014–306775

[22] Jhund P.S., McMurray J.J.V. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan // Heart. 2016. Vol. 102, No. 17. P. 1342–1347. DOI: 10.1136/heartjnl-2014-306775

[23] Vilela-Martin JF. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Devel Ther. 2016;10:1627–1639. DOI: 10.2147/DDDT.S84782

[24] Vilela-Martin J.F. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date // Drug Des Devel Ther. 2016. Vol. 10. P. 1627–1639. DOI: 10.2147/DDDT.S84782

[25] Webster CI, Burrell M, Olsson LL, et al. Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer’s disease. PLoS One. 2014;9(8): e104001.DOI: 10.1371/journal.pone.0104001

[26] Webster C.I., Burrell M., Olsson L.L., et al. Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer’s disease // PLoS One. 2014. Vol. 9, No. 8. P. e104001.DOI: 10.1371/journal.pone.0104001

[27] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. DOI: 10.1056/NEJMoa1409077

[28] McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure // N Engl J Med. 2014. Vol. 371. P. 993–1004. DOI: 10.1056/NEJMoa1409077

RIGHTS & PERMISSIONS

ECO-vector LLC